Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2016

View Archived Issues

Profounda announces launch of Impavido in the U.S.

Thomson Reuters Drug News Publication Holidays

Regen BioPharma submits IND application for tCellVax to the FDA

Bayer Schering Pharma patents AKR1C3 inhibitors

Novartis discloses Raf kinase C and B inhibitors

Chiesi Farmaceutici develops PI3K inhibitors

GlaxoSmithKline divulges Ret inhibitors

Initiation of phase II study evaluating AGS-003 for the treatment of NSCLC

Boehringer Ingelheim Pharma reports DPP-I inhibitors

BioLineRx starts phase II trial for BL-8040 as novel stem cell mobilization treatment

Novel targets and animal models presented at EAU

First subject dosed in phase Ia healthy volunteer study evaluating SNS-062

Host cell protein complex identified as a potential HBV therapy target

Bio-Path and UT Southwestern enter SLE research agreement

Bristol-Myers Squibb to acquire Padlock Therapeutics

Ultragenyx and Saint Louis University to develop muscular dystrophy treatments

RMC-035, a novel drug candidate for treating pre-eclampsia

Novel liver-directed glucokinase activator discovered at Advinus

OncoTherapy confirms positive phase I results for OTSA-101

ITM Isotopen Technologien Munchen and Scil Proteins partner on targeted radio conjugates

Agilis Biotherapeutics and T-TOP Clinical Research to collaborate on AADC deficiency gene therapy

FDA approves Cinqair injection

Vernalis presents Chk1 inhibitor VER-250840

Roche submits Elecsys BRAHMS PCT sepsis assay to the FDA

Swedish Orphan Biovitrum becomes marketing authorisation holder of efmoroctocog alfa in the E.U.

Eisai withdraws NDA for ultra-high dose mecobalamin in Japan

Phase IIb trial of NTCELL for Parkinson's disease underway in New Zealand

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...